Pillars of growth
Heavy bet for R&D
as a future
growth engine
Heavy bet on R&D
as a future
growth engine
Biosimilars
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.
Pharmaceutical products
Diversified portfolio of innovative own and licensed products protected by patents.
Low Molecular Weight Heparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.
CDMO
High production capacity with four the manufacturing plants for prefilled syringes and oral solid forms.
Rovi in figures
763.7 Mn€
Operatig revenuein 2024
427.5 Mn€
Specialty Pharmaceutical business Sales in 2024 (+2% vs 2023)
+60
countries
LMWH presence through strategic alliances with international partners
25.8 Mn€
R&D expenses in 2024 (+3% vs 2023)
336.2 Mn€
CDMO Sales in 2024
16.1 points
Low risk at Sustainalytics’ global pharmaceutical industry ranking
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.
Last news on Rovi
25/03/2025
Last annual report
Sustainability report 2024
Last regular
public information
Presentation 2024
